Nutritional Supplementation in Cognitive Aging

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00599508

Enrollment

120

Registered

2008-01-23

Start date

2006-06-30

Completion date

2015-01-31

Last updated

2016-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Aging

Keywords

memory, aging

Brief summary

To evaluate the effect of supplemented berry fruit juice and whole fruit berry powder on memory performance and brain function in older adults

Detailed description

Randomized trials involving daily supplementation with berry fruits in older adults with early memory changes. The berry products include Concord grape juice, blueberry juice, and whole fruit blueberry powder. Supplementation periods are 12 and 16 weeks, depending on berry product. The Aims of the studies are to assess effects on cognitive performance and in a subset of participants, in brain activity.

Interventions

DIETARY_SUPPLEMENTConcord grape juice

Several ounces Concord grape juice administered 3 times a day for 12 or 16 weeks. Specific dosage determined by participant's weight.

DIETARY_SUPPLEMENTplacebo juice

several ounces placebo juice consumed three times a day for 12 or 16 weeks; dosage determined according to participant's weight

DIETARY_SUPPLEMENTblueberry juice

wild blueberry juice administered daily for 12 weeks, dosage determined according to participant's weight

DIETARY_SUPPLEMENTwhole fruit blueberry powder

whole fruit, freeze dried blueberry powder derived from a blend of cultivated blueberries administered daily for 16 weeks

DIETARY_SUPPLEMENTberry placebo powder

berry placebo powder administered daily for 16 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

66 Years to No maximum

Healthy volunteers

Inclusion criteria

* Mild Cognitive Impairment

Exclusion criteria

* Diabetes * Weight of under 100 or over 210 pounds * Chronic use of pain medication

Design outcomes

Primary

Measure	Time frame
memory performance	at the end of the intervention

Secondary

Measure	Time frame
cortisol	at the end of the intervention

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026